A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer, according to a study published in Nature Medicine.
May 23, 2022
0
61
(HealthDay)—In the United States, more patients are being diagnosed with stage I non-small cell lung cancer (NSCLC), and five-year survival for NSCLC has increased, according to a study published online Oct. 21 in JAMA ...
Nov 3, 2021
0
1
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent ...
Sep 19, 2021
0
62
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how basic science advances will impact clinical ...
Aug 12, 2021
0
331
(HealthDay)—For patients with non-small cell lung cancer (NSCLC), smoking cessation after diagnosis is associated with a reduced risk for all-cause mortality, cancer-specific mortality, and disease progression, according ...
Jul 27, 2021
0
1
A study led by D. Ross Camidge, MD, Ph.D., director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare but potentially actionable ...
Jul 20, 2021
0
1
A research team led by Prof. Wang Yuexiang from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences discovered a novel oncogenic driver gene in human lung cancer, the leading cause of ...
Jun 22, 2021
0
2
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was ...
Jun 10, 2021
0
1
Lung cancer is a major global cause of mortality, reportedly accounting for 1.7 million deaths each year. The most common form of lung cancer is non-small-cell lung cancer (NSCLC), and early-stage NSCLCs can often be surgically ...
Apr 23, 2021
0
86
Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harboring this mutation, according to results from a study with ...
Mar 25, 2021
0
2
